Status:
COMPLETED
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Lead Sponsor:
National Medical Research Radiological Centre of the Ministry of Health of Russia
Conditions:
Covid19
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Coronavirus disease (COVID-19) is a pandemic of unprecedented proportions with an exponential increase in incidence. Airway epithelium infection caused by coronavirus (SARS-CoV-2) triggers a cascade o...
Eligibility Criteria
Inclusion
- Positive SARS-Cov-2 polymerase chain reaction (PCR)
- CT confirmed pneumonia
- Men and non-pregnant women ≥ 18 y/o with early laboratory signs of cytokine storm
- Men and non-pregnant women \<65 y/o and/or with early laboratory signs of cytokine storm
- Informed consent obtained for participation
Exclusion
- Age ≤ 18
- Severe course of COVID-19
- Pregnant or breast-feeding females
- Severe concomitant pathology
- Previous and/or present treatment of oncology disease (e.g. immunotherapy)
- Autoimmune diseases, severe cardiac disease, bone marrow and/or visceral transplantation
- Surgical treatment and/or radiotherapy of chest pathology
- Treatment with specific antiviral and anticytokine agents a day before inhalation procedure
- Absence of informed consent obtained for participation
Key Trial Info
Start Date :
October 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04724538
Start Date
October 15 2020
End Date
March 15 2021
Last Update
July 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
P. Hertsen Moscow Oncology Research Institute
Moscow, Russia, 125284